Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Share Incentive Scheme

26 Apr 2024 10:02

RNS Number : 2189M
Intercede Group PLC
26 April 2024
Β 

Β 

Β 

26 April 2024

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

Β 

Share Incentive Scheme

Β 

Further to the announcement dated 13 March 2014, which provides details of the Company's Share Incentive Plan, the Company confirms that Klaas van der Leest (CEO) and Nitil Patel (CFO) (the "Directors") have each made binding commitments to subscribe for Β£1,800 of Partnership Shares from the April 2024 payroll at the prevailing market price on that date. Matching Shares will also be given to the Directors on the basis of one Matching Share for each Partnership Share.

Β 

The Directors' updated interests in the shares of the Company will be notified immediately following the completion of these transactions.

Β 

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

Β 

Β 

Cavendish Capital Markets Limited

Tel. + 44 (0)20 7220 0500

Simon Hicks/Fergus Sullivan

Corporate Finance

Tim Redfern

ECM

Β 

About Intercede

Intercede is a cybersecurity software company specialising in digital identities, and its innovative solutions enable organisations to protect themselves against the number one cause of data breach: compromised user credentials.

Β 

The Intercede suite of products allows customers to choose the level of security that best fits their needs, from Secure Registration and ID Verification to Password Security Management, One-Time Passwords, FIDO and PKI.Β Uniquely, Intercede provides the entire set of authentication options from Passwords to PKI, supporting customers on their journey to passwordless and stronger authentication environments. In addition to developing and supporting Intercede software, the Group offers professional services and custom development capabilities as well as managing the world's largest password breach database.

Β 

For over 20 years, global customers in government, aerospace and defence, financial services, healthcare, telecommunications, cloud services and information technology have trusted Intercede solutions and expertise in protecting their mission critical data and systems at the highest level of assurance.

For more information visit: www.intercede.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCUNVWRSVUSURR
Date   Source Headline
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20247:00 amRNSTransaction in Own Shares
14th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSNotice of Results & Investor Presentation
25th Oct 20247:00 amRNSShare Buyback Programme
11th Oct 20248:38 amRNSDirector/PDMR Shareholding
8th Oct 20247:00 amRNSTrading Update
1st Oct 20247:00 amRNSNotification of Trading Update and H1 FY25 Results
30th Sep 20247:00 amRNSContract Orders and Renewals
25th Sep 202412:51 pmRNSResult of AGM
20th Sep 202411:45 amRNSDirector/PDMR Shareholding
18th Sep 20247:00 amRNSContract Orders and Renewals
2nd Sep 20247:00 amRNSContract Orders and Subscription Renewals
30th Aug 20247:00 amRNSNotice of AGM and Publication of Annual Report
4th Jul 20243:58 pmRNSIssue of Equity & Total Voting Rights
28th Jun 20243:49 pmRNSIssue of Equity & Total Voting Rights
26th Jun 20247:00 amRNSPartnership with Carahsoft Technology Corp
19th Jun 20246:25 pmRNSHolding(s) in Company
18th Jun 20249:17 amRNSHolding(s) in Company
18th Jun 20247:15 amRNSDirector/PDMR Shareholding and Issue of Equity
18th Jun 20247:00 amRNSFinal Results
5th Jun 20247:00 amRNSNotice of Results & Investor Presentation
16th May 202412:00 pmRNSCapital Markets Day - Agenda Update
14th May 20246:17 pmRNSShare Incentive Scheme
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.